Navigation Links
New Data Supports Significant Economic and Clinical Value of MENOPUR(R) in IVF
Date:6/30/2009

AMSTERDAM, The Netherlands, June 30 /PRNewswire/ --

- "Study Could Have Major Impact on the Decision-Making Process With Respect to Infertility Treatment"

New data from an economic analysis presented today at this year's European Society of Human Reproduction and Embryology (ESHRE) congress showed that, within the parameters of the simulation model used, the in vitro fertilisation (IVF) treatment MENOPUR (highly-purified human menopausal gonatropin or HP-hMG) offered considerable cost-savings over recombinant follicle stimulating hormone (rFSH).[1] The cost-effectiveness of HP-hMG compared with rFSH suggested by this data could make it a more attractive choice for use in infertility treatment within a fixed healthcare budget.

In today's difficult global financial situation, the cost-effectiveness of infertility treatments, such as IVF, is more important than ever. Experiencing fertility problems is deeply distressing and isolating for couples and the cost of treatment is one of many considerations for people seeking treatment. A recent audit of European infertility patient groups showed that infertile couples are calling for clear information on the cost-effectiveness, as well as the efficacy of individual treatments.[2]

HP-hMG and rFSH are two commonly used hormonal therapies belonging to the class of drugs known as gonadotropins that enhance egg production in IVF treatment. HP-hMG, contains both FSH and hCG-driven (human chorionic gonadotropin) LH-activity (luteinizing hormone). In contrast, rFSH is a recombinant product and contains only rFSH.

"Until recently, discussions regarding funding for infertility treatment services have been hindered by a relative paucity of economic studies of the specific treatments," points out study investigator Dr Jaro Wex from PharmArchitecture, UK.

"Our new study compared success rates and value for money of gonadot
'/>"/>

SOURCE Ferring Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. New Study Supports Efficacy of Vagus Nerve Stimulation for Treatment-Resistant Depression
2. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
3. Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer
4. Cost-Effectiveness Study Supports Use of EUFLEXXA(TM) by Rheumatologists for Pain Relief in Patients with Knee Osteoarthritis
5. New Data from the Framingham Heart Study Supports PAT Technology to Diagnose Early Cardiovascular Disease
6. Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood
7. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
8. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
9. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
10. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
11. New Clinical Data Further Supports Chromium Picolinates Role in Enhancing Brain Activity in Older Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... LAWRENCEVILLE, N.J. , Jan. 15, 2014  Celsion Corporation (the ... it has received commitments from institutional investors to purchase ... common stock in an at-the-market registered direct offering, led ... Company entered into definitive purchase agreements with these investors ...
(Date:1/15/2014)... Jan. 15, 2014  Manufacturers, suppliers and distributors of ... to protect their most important business assets, intellectual ... ) Because of the highly-competitive nature ... one of the most litigious industry sectors of ...
(Date:1/15/2014)... GENEVA, Ill. , Jan. 15, 2014 The ... a Medical Fitness Center by the Medical Fitness Association, ... centers to achieve their full potential. The Cadence Fitness ... in the western suburbs and second in the Chicagoland ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3
... WALTHAM, Mass. , July 21 Alere Inc. ... ), a global leader in enabling individuals to take charge of ... health management, today announced that it will release its second quarter ... will also host a conference call beginning at 10:00 a.m. ...
... July 21 EndoChoice, Inc. today announced that it has moved ...  The new 30,000 square foot corporate headquarters is three times larger than ... , , ... a seamless move into our new corporate headquarters," stated EndoChoice CEO and ...
Cached Medicine Technology:Alere Inc. Schedules Conference Call for 10:00 a.m. ET July 28, 2010 to Discuss Second Quarter 2010 Results 2EndoChoice® Triples Facility Space to Address Growing Customer Base 2
(Date:4/23/2014)... University researchers have developed a way to detect and ... tiny gold particles with tails of synthetic DNA., A ... biological engineering, used gold nanoparticles to target and bind ... RNA splice variants, which can indicate the presence and ... splice variants in a cell can be determined by ...
(Date:4/23/2014)... A novel compound that targets an important brain receptor ... addiction behaviors, including relapse behavior, a University at Buffalo ... evidence that this may be a novel lead compound ... exist., The UB research was published as an online ... In the study, the compound, RO5263397, severely blunted a ...
(Date:4/23/2014)... 23, 2014Men whose testosterone falls below normal levels are ... overweight and have heart disease and type 2 diabetes. ... men for further testing and possible treatment is described ... , a peer-reviewed publication from Mary Ann Liebert, Inc., ... Journal of Men,s Health website at http://www.liebertpub.com/jmh ...
(Date:4/23/2014)... "simple and accessible detection methods that can rapidly ... of a single cell inside that population has ... Chang Lu. , In the Royal Society of ... announced that he and his coworkers have developed ... of a protein ( Chem. Sci. , 2014, ...
(Date:4/23/2014)... health benefits of probiotics, antioxidants and other nutritional compounds, ... chemical industry is getting in on the action. But ... so the industry is responding with clinical research to ... in Chemical & Engineering News (C&EN), the ... Melody M. Bomgardner, a senior editor at C&EN, writes ...
Breaking Medicine News(10 mins):Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2Health News:Novel compound halts cocaine addiction and relapse behaviors 2Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2
... they travel, they pack a lunch. In results ... evolutionary biologists Joan Strassmann and David Queller of Rice ... known as slime molds) increase their odds of survival ... lead author Debra Brock, a graduate student at Rice, ...
... News) -- Many U.S. transplant surgeons unnecessarily shun organs ... safeguards that would protect and inform transplant recipients, a ... in the nation "overreacted" to a 2007 case in ... organs from a single donor unknowingly infected with HIV, ...
... HealthDay Reporter , TUESDAY, Jan. 18 (HealthDay News) -- A ... II colon cancer face a higher risk of recurrence, German ... doctors in determining which patients need follow-up treatment after initial ... improvement on existing ways to predict recurrence, according to cancer ...
... who had not discussed life support measures with critically ... to forego further medical intervention than those who had ... the University of Pittsburgh School of Medicine and the ... in a poster presentation at the Society of Critical ...
... have been hot on the trail of a genetic mutation ... mutation,s discovery in 2008. The hunt is now yielding fruit. ... , researchers reveal how the mutation contributes to cancer development ... 75 percent of people with low-grade brain tumors and 20 ...
... January 18, 2011 HIV-positive head and neck cancer ... similar toxicity rates as non-HIV-positive patients, despite prior reports ... January issue of the International Journal of Radiation ... for Radiation Oncology (ASTRO). , Patients with HIV have ...
Cached Medicine News:Health News:Like humans, amoebae pack a lunch before they travel 2Health News:Gene Test Might Predict Colon Cancer's Return 2Health News:Gene Test Might Predict Colon Cancer's Return 3Health News:Pitt study: End-of-life decisions take longer if patient hasn't shared wishes with family 2Health News:Molecular battle in cancer cells offers clues for treatment 2Health News:HIV-positive head and neck cancer patients benefit from radiation therapy 2
... The ICD-9-CM contains the numerical list of ... for your Palm or Pocket PC PDA ... Ninth Revision, Clinical Modification (ICD-9-CM) is based ... International Classification of Diseases (ICD-9). ICD-9-CM is ...
The focus of HandEchart Professional is to offer a practical and basic electronic patient record keeping system that anyone can learn in minutes....
Archimedes is an innovative specialty calculator. Forget having to remember complicated formulas, just enter the values and out come the results....
A handy, quick reference for physicians, nurses, and other health care providers treating cancer patients....
Medicine Products: